Levels of 15-HETE and TXB2 in exhaled breath condensates as markers for diagnosis of childhood asthma and its therapeutic outcome

Li Chen Chen; Hsu Min Tseng; Ming Ling Kuo; Chih Yung Chiu; Sui Ling Liao; Kuan Wen Su; Ming Han Tsai; Man Chin Hua; Shen Hao Lai; Tsung Chieh Yao; Kuo Wei Yeh; Ai Hsuan Wu; Hsiu Yueh Yu; Jing Long Huang; Shau Ku Huang

doi:10.1111/pai.13587

Levels of 15-HETE and TXB₂ in exhaled breath condensates as markers for diagnosis of childhood asthma and its therapeutic outcome

Li Chen Chen, Hsu Min Tseng, Ming Ling Kuo, Chih Yung Chiu, Sui Ling Liao, Kuan Wen Su, Ming Han Tsai, Man Chin Hua, Shen Hao Lai, Tsung Chieh Yao, Kuo Wei Yeh, Ai Hsuan Wu, Hsiu Yueh Yu, Jing Long Huang, Shau Ku Huang

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Background: Dysregulation of eicosanoids is associated with asthma and a composite of oxylipins, including exhaled leukotriene B₄ (LTB₄), characterizes childhood asthma. While fractional exhaled nitric oxide (FeNO) has been used as the standard for monitoring steroid responsiveness, the potential utility of eicosanoids in monitoring the therapeutic outcomes remains unclear. We aimed to examine the levels of major eicosanoids representing different metabolic pathways in exhaled breath condensates (EBCs) of children with asthma during exacerbation and after treatment. Methods: Levels of 6 exhaled eicosanoid species in asthmatic children and healthy subjects were evaluated using ELISA. Results: In addition to those previously reported, including LTB₄, the levels of exhaled 15-hydroxyeicosatetraenoic acid (15-HETE), but not thromboxane B₂ (TXB₂), showed significant difference between asthmatics (N = 318) and healthy controls (N = 97), particularly the severe group showed the lowest levels of exhaled 15-HETE. Receiver operating characteristic (ROC) curve analyses revealed similar distinguishing power for the levels of 15-HETE, FEV₁ (forced expiratory volume in the first second), and FeNO, while the 15-HETE/LTB₄ ratio was significantly lower in subjects with asthma as compared to that of healthy controls (p < 0.0001). Analysis of asthmatics (N = 75) during exacerbation and convalescence showed significant improvement in lung function (FEV₁, p <.001), but not FeNO, concomitant with significantly increased levels of 15-HETE (p <.001) and reduced levels of TXB₂ (p <.05) at convalescence, particularly for those who at the top 30% level during exacerbation. Further, decreased LTB₄ and lipoxin A₄ (LXA₄) at convalescence were noted only in those at the top 30 percentile during exacerbation. Conclusion: The exhaled 15-HETE was found to discriminate childhood asthma while decreased levels of exhaled TXB₂ and increased levels of 15-HETE were prominent at convalescence.

Original language	English
Pages (from-to)	1673-1680
Number of pages	8
Journal	Pediatric Allergy and Immunology
Volume	32
Issue number	8
DOIs	https://doi.org/10.1111/pai.13587
Publication status	Published - Nov 2021
Externally published	Yes

Keywords

15-HETE
childhood asthma
exhaled breath condensates
TXB

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Immunology and Allergy
Immunology

Access to Document

10.1111/pai.13587

Cite this

Chen, L. C., Tseng, H. M., Kuo, M. L., Chiu, C. Y., Liao, S. L., Su, K. W., Tsai, M. H., Hua, M. C., Lai, S. H., Yao, T. C., Yeh, K. W., Wu, A. H., Yu, H. Y., Huang, J. L., & Huang, S. K. (2021). Levels of 15-HETE and TXB₂ in exhaled breath condensates as markers for diagnosis of childhood asthma and its therapeutic outcome. Pediatric Allergy and Immunology, 32(8), 1673-1680. https://doi.org/10.1111/pai.13587

Chen, LC, Tseng, HM, Kuo, ML, Chiu, CY, Liao, SL, Su, KW, Tsai, MH, Hua, MC, Lai, SH, Yao, TC, Yeh, KW, Wu, AH, Yu, HY, Huang, JL & Huang, SK 2021, 'Levels of 15-HETE and TXB₂ in exhaled breath condensates as markers for diagnosis of childhood asthma and its therapeutic outcome', Pediatric Allergy and Immunology, vol. 32, no. 8, pp. 1673-1680. https://doi.org/10.1111/pai.13587

@article{3f1f673ed7114b1aa50c859fe8885125,

title = "Levels of 15-HETE and TXB2 in exhaled breath condensates as markers for diagnosis of childhood asthma and its therapeutic outcome",

abstract = "Background: Dysregulation of eicosanoids is associated with asthma and a composite of oxylipins, including exhaled leukotriene B4 (LTB4), characterizes childhood asthma. While fractional exhaled nitric oxide (FeNO) has been used as the standard for monitoring steroid responsiveness, the potential utility of eicosanoids in monitoring the therapeutic outcomes remains unclear. We aimed to examine the levels of major eicosanoids representing different metabolic pathways in exhaled breath condensates (EBCs) of children with asthma during exacerbation and after treatment. Methods: Levels of 6 exhaled eicosanoid species in asthmatic children and healthy subjects were evaluated using ELISA. Results: In addition to those previously reported, including LTB4, the levels of exhaled 15-hydroxyeicosatetraenoic acid (15-HETE), but not thromboxane B2 (TXB2), showed significant difference between asthmatics (N = 318) and healthy controls (N = 97), particularly the severe group showed the lowest levels of exhaled 15-HETE. Receiver operating characteristic (ROC) curve analyses revealed similar distinguishing power for the levels of 15-HETE, FEV1 (forced expiratory volume in the first second), and FeNO, while the 15-HETE/LTB4 ratio was significantly lower in subjects with asthma as compared to that of healthy controls (p < 0.0001). Analysis of asthmatics (N = 75) during exacerbation and convalescence showed significant improvement in lung function (FEV1, p <.001), but not FeNO, concomitant with significantly increased levels of 15-HETE (p <.001) and reduced levels of TXB2 (p <.05) at convalescence, particularly for those who at the top 30% level during exacerbation. Further, decreased LTB4 and lipoxin A4 (LXA4) at convalescence were noted only in those at the top 30 percentile during exacerbation. Conclusion: The exhaled 15-HETE was found to discriminate childhood asthma while decreased levels of exhaled TXB2 and increased levels of 15-HETE were prominent at convalescence.",

keywords = "15-HETE, childhood asthma, exhaled breath condensates, TXB",

author = "Chen, {Li Chen} and Tseng, {Hsu Min} and Kuo, {Ming Ling} and Chiu, {Chih Yung} and Liao, {Sui Ling} and Su, {Kuan Wen} and Tsai, {Ming Han} and Hua, {Man Chin} and Lai, {Shen Hao} and Yao, {Tsung Chieh} and Yeh, {Kuo Wei} and Wu, {Ai Hsuan} and Yu, {Hsiu Yueh} and Huang, {Jing Long} and Huang, {Shau Ku}",

note = "Funding Information: This work was supported by Chang Gung Memorial Hospital (CMRPG3G2051, CMRPVVK0161), the Ministry of Science and Technology, Taiwan (MOST 108‐2314‐B‐182A‐088), and, in part, by a grant from National Health Research Institutes, Taiwan (EO‐109‐PP‐10). Publisher Copyright: {\textcopyright} 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.",

year = "2021",

month = nov,

doi = "10.1111/pai.13587",

language = "English",

volume = "32",

pages = "1673--1680",

journal = "Pediatric Allergy and Immunology",

issn = "0905-6157",

publisher = "Blackwell Munksgaard",

number = "8",

}

TY - JOUR

T1 - Levels of 15-HETE and TXB2 in exhaled breath condensates as markers for diagnosis of childhood asthma and its therapeutic outcome

AU - Chen, Li Chen

AU - Tseng, Hsu Min

AU - Kuo, Ming Ling

AU - Chiu, Chih Yung

AU - Liao, Sui Ling

AU - Su, Kuan Wen

AU - Tsai, Ming Han

AU - Hua, Man Chin

AU - Lai, Shen Hao

AU - Yao, Tsung Chieh

AU - Yeh, Kuo Wei

AU - Wu, Ai Hsuan

AU - Yu, Hsiu Yueh

AU - Huang, Jing Long

AU - Huang, Shau Ku

N1 - Funding Information: This work was supported by Chang Gung Memorial Hospital (CMRPG3G2051, CMRPVVK0161), the Ministry of Science and Technology, Taiwan (MOST 108‐2314‐B‐182A‐088), and, in part, by a grant from National Health Research Institutes, Taiwan (EO‐109‐PP‐10). Publisher Copyright: © 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

PY - 2021/11

Y1 - 2021/11

N2 - Background: Dysregulation of eicosanoids is associated with asthma and a composite of oxylipins, including exhaled leukotriene B4 (LTB4), characterizes childhood asthma. While fractional exhaled nitric oxide (FeNO) has been used as the standard for monitoring steroid responsiveness, the potential utility of eicosanoids in monitoring the therapeutic outcomes remains unclear. We aimed to examine the levels of major eicosanoids representing different metabolic pathways in exhaled breath condensates (EBCs) of children with asthma during exacerbation and after treatment. Methods: Levels of 6 exhaled eicosanoid species in asthmatic children and healthy subjects were evaluated using ELISA. Results: In addition to those previously reported, including LTB4, the levels of exhaled 15-hydroxyeicosatetraenoic acid (15-HETE), but not thromboxane B2 (TXB2), showed significant difference between asthmatics (N = 318) and healthy controls (N = 97), particularly the severe group showed the lowest levels of exhaled 15-HETE. Receiver operating characteristic (ROC) curve analyses revealed similar distinguishing power for the levels of 15-HETE, FEV1 (forced expiratory volume in the first second), and FeNO, while the 15-HETE/LTB4 ratio was significantly lower in subjects with asthma as compared to that of healthy controls (p < 0.0001). Analysis of asthmatics (N = 75) during exacerbation and convalescence showed significant improvement in lung function (FEV1, p <.001), but not FeNO, concomitant with significantly increased levels of 15-HETE (p <.001) and reduced levels of TXB2 (p <.05) at convalescence, particularly for those who at the top 30% level during exacerbation. Further, decreased LTB4 and lipoxin A4 (LXA4) at convalescence were noted only in those at the top 30 percentile during exacerbation. Conclusion: The exhaled 15-HETE was found to discriminate childhood asthma while decreased levels of exhaled TXB2 and increased levels of 15-HETE were prominent at convalescence.

AB - Background: Dysregulation of eicosanoids is associated with asthma and a composite of oxylipins, including exhaled leukotriene B4 (LTB4), characterizes childhood asthma. While fractional exhaled nitric oxide (FeNO) has been used as the standard for monitoring steroid responsiveness, the potential utility of eicosanoids in monitoring the therapeutic outcomes remains unclear. We aimed to examine the levels of major eicosanoids representing different metabolic pathways in exhaled breath condensates (EBCs) of children with asthma during exacerbation and after treatment. Methods: Levels of 6 exhaled eicosanoid species in asthmatic children and healthy subjects were evaluated using ELISA. Results: In addition to those previously reported, including LTB4, the levels of exhaled 15-hydroxyeicosatetraenoic acid (15-HETE), but not thromboxane B2 (TXB2), showed significant difference between asthmatics (N = 318) and healthy controls (N = 97), particularly the severe group showed the lowest levels of exhaled 15-HETE. Receiver operating characteristic (ROC) curve analyses revealed similar distinguishing power for the levels of 15-HETE, FEV1 (forced expiratory volume in the first second), and FeNO, while the 15-HETE/LTB4 ratio was significantly lower in subjects with asthma as compared to that of healthy controls (p < 0.0001). Analysis of asthmatics (N = 75) during exacerbation and convalescence showed significant improvement in lung function (FEV1, p <.001), but not FeNO, concomitant with significantly increased levels of 15-HETE (p <.001) and reduced levels of TXB2 (p <.05) at convalescence, particularly for those who at the top 30% level during exacerbation. Further, decreased LTB4 and lipoxin A4 (LXA4) at convalescence were noted only in those at the top 30 percentile during exacerbation. Conclusion: The exhaled 15-HETE was found to discriminate childhood asthma while decreased levels of exhaled TXB2 and increased levels of 15-HETE were prominent at convalescence.

KW - 15-HETE

KW - childhood asthma

KW - exhaled breath condensates

KW - TXB

UR - http://www.scopus.com/inward/record.url?scp=85110071203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85110071203&partnerID=8YFLogxK

U2 - 10.1111/pai.13587

DO - 10.1111/pai.13587

M3 - Article

C2 - 34176158

AN - SCOPUS:85110071203

SN - 0905-6157

VL - 32

SP - 1673

EP - 1680

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

IS - 8

ER -